Antepartum Hemorrhage
Introduction
Background
Antepartum hemorrhage refers to any vaginal bleeding that occurs after 20 weeks of gestation but before the onset of labor. It is a critical obstetric complication that can signify a range of underlying conditions, some of which pose significant risks to both the pregnant individual and the fetus. The occurrence of bleeding during this period requires immediate medical attention to determine its cause and guide appropriate management.
Biological Basis
The biological mechanisms underlying antepartum hemorrhage are varied, frequently stemming from issues at the placental-uterine interface or within the maternal reproductive tract. Key causes include placenta previa, a condition where the placenta partially or completely covers the cervix, and placental abruption, which involves the premature separation of the placenta from the uterine wall. Other potential causes include vasa previa, where fetal blood vessels are unprotected and cross the cervical os, and, less commonly, uterine rupture. These conditions lead to bleeding through mechanisms such as vascular disruption, tissue detachment, or compromised structural integrity. While many instances are linked to physiological or mechanical factors, there may be a genetic component influencing susceptibility to some of the predisposing conditions. Genetic variations impacting vascular health, coagulation pathways, or tissue strength could play a role in an individual's risk profile, highlighting the complex and multifactorial nature of genetic contributions to such obstetric complications.
Clinical Relevance
Antepartum hemorrhage is a significant clinical concern due to its potential for severe maternal and fetal morbidity and mortality. Prompt and accurate diagnosis is essential, typically involving a comprehensive clinical assessment, ultrasound imaging to locate the placenta and assess fetal well-being, and laboratory tests to evaluate blood loss and clotting status. Management strategies are highly dependent on the identified cause, the severity of the bleeding, the gestational age of the fetus, and the overall maternal and fetal condition. These may range from expectant management with close monitoring to urgent medical interventions or emergency delivery. Timely diagnosis and appropriate clinical management are paramount for optimizing outcomes for both the mother and the baby.
Social Importance
Beyond its direct medical implications, antepartum hemorrhage carries considerable social importance. It can lead to prolonged hospitalizations, increased healthcare expenditures, and substantial emotional distress for expectant parents and their families. The potential for serious adverse outcomes, including preterm birth, fetal distress, stillbirth, or severe maternal complications suchs as massive hemorrhage and hysterectomy, can have lasting psychological and social consequences. Public health initiatives aim to enhance prenatal care, identify individuals at higher risk, and ensure access to specialized obstetric services to mitigate the overall burden of antepartum hemorrhage on individuals, families, and healthcare systems.
Methodological and Statistical Considerations
Many genetic studies face limitations due to relatively small sample sizes, which can reduce statistical power to detect genetic associations and potentially lead to an overestimation of effect sizes for identified variants. [1] Differences in sample size across various cohorts, or between discovery and replication stages, can also contribute to inconsistencies in findings, making robust replication challenging. [2] This suggests that some true genetic associations with modest effect sizes might remain undetected, and reported associations may require further validation in larger, independent cohorts to confirm their reliability.
The design of genetic studies can introduce specific biases that affect the interpretation of results. For instance, a case-only study design, while valuable for identifying genetic modifiers within affected populations, does not assess overall disease risk and may be susceptible to selection bias. [1] Furthermore, studies may inadvertently exclude individuals with severe phenotypes who die before hospital admission, potentially skewing the genetic profile of the studied cohort towards less severe or more chronic forms of the condition. [1] Systematic inflation in association results, often stemming from unaddressed population stratification or other systematic biases, necessitates careful statistical adjustments but can still impact the reliability of reported associations. [3]
Phenotypic Heterogeneity and Measurement Challenges
The accurate and consistent definition of complex disease phenotypes is crucial for robust genetic association studies, yet it presents inherent challenges. Issues can arise from potential misclassification of disease subtypes, such as distinguishing between lobar and non-lobar forms, even when classification methods have demonstrated good reliability. [1] Such misclassification can dilute specific genetic signals or, conversely, lead to spurious associations, complicating the identification of precise genetic pathways underlying distinct disease presentations.
The reliance on certain diagnostic modalities without complementary advanced imaging techniques can limit the depth of phenotypic characterization. For example, the use of computed tomography (CT) scans without magnetic resonance imaging (MRI) can mean missing additional information about underlying pathologies, which might hinder a more precise phenotypic classification and the discovery of associated genetic variants. [1] Moreover, variations in genetic imputation reference panels used across different studies, such as the Haplotype Reference Consortium versus the 1000 Genomes Project, can introduce inconsistencies in the imputed genetic data, contributing to heterogeneity in results and complicating meta-analyses. [2]
Population Diversity and Knowledge Gaps
A significant limitation in many genetic association studies is the predominant focus on populations of European ancestry. [1] This narrow representation restricts the generalizability of findings to other ethnic or racial groups, as genetic architectures and allele frequencies can vary substantially across diverse populations. [3] Consequently, genetic loci identified in one population may not be relevant or exert the same effect size in non-European populations, potentially contributing to health disparities by impeding the development of universally effective precision medicine strategies.
While genetic studies typically account for known confounders like age, sex, and population structure, the intricate interplay between genetic predispositions and environmental factors often remains largely unexplored. [2] The absence of comprehensive environmental data collection limits the ability to identify critical gene-environment interactions, which are essential for fully understanding disease etiology and the phenomenon of "missing heritability." Furthermore, areas such as the utility of advanced neuroimaging for more precise disease classification represent ongoing knowledge gaps that, if addressed, could significantly refine our understanding of disease mechanisms and genetic influences. [1]
Variants
The TRPM6 gene encodes a protein that forms a channel crucial for the absorption of magnesium in the intestines and its reabsorption in the kidneys, playing a vital role in maintaining the body's magnesium balance. Magnesium is an essential mineral involved in over 300 biochemical reactions, influencing critical physiological processes such as muscle and nerve function, blood glucose control, blood pressure regulation, and maintaining bone health. Proper magnesium homeostasis is fundamental for overall cellular function and systemic health, with imbalances potentially leading to a wide array of health issues. Genetic studies have extensively investigated various loci associated with different forms of hemorrhage, underscoring the complex genetic architecture that underlies these conditions . [3], [4]
The variant rs1422850991 is located within the TRPM6 gene, and its presence can potentially influence the gene's function. Variants in TRPM6 can impact the structure or activity of the magnesium channel, leading to impaired magnesium transport and absorption. Such alterations can result in conditions like primary hypomagnesemia with secondary hypocalcemia, characterized by severe magnesium deficiency. The functional consequence of rs1422850991 may include reduced efficiency of magnesium uptake, contributing to lower systemic magnesium levels, which can have cascading effects on cellular and organ systems. The ongoing efforts in genome-wide association studies continue to reveal the genetic underpinnings of various cerebrovascular diseases and aspects of vascular integrity. [2]
Dysregulation of magnesium, potentially influenced by variants like rs1422850991, can have significant implications for vascular health and coagulation pathways. Magnesium is a natural calcium channel blocker and vasodilator, contributing to the regulation of blood pressure and endothelial function. It also plays a role in platelet aggregation and the intricate cascade of blood clotting. Therefore, severe hypomagnesemia can compromise vascular integrity and alter coagulation, potentially increasing the risk of bleeding disorders. In the context of pregnancy, maintaining optimal magnesium levels is crucial, as magnesium deficiencies could theoretically predispose individuals to complications such as antepartum hemorrhage by affecting vascular stability or contributing to impaired hemostasis . [3], [4]
The provided research material does not contain information regarding the signs and symptoms of antepartum hemorrhage.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs1422850991 | TRPM6 | antepartum hemorrhage |
Genetic Predisposition and Heritability
Genetic factors play a significant role in the susceptibility to various pregnancy complications, including those that can lead to antepartum hemorrhage. Genome-wide association studies (GWAS) have identified specific genetic variants associated with traits relevant to pregnancy outcomes, such as glycemic traits, where genes like HKDC1 and BACE2 have been implicated. [5] Beyond single gene effects, the cumulative impact of multiple common genetic variants, known as polygenic risk, contributes to the overall risk of conditions like preterm birth and preeclampsia. [6] For instance, clotting factor genes have been associated with preeclampsia in specific populations, suggesting a genetic predisposition to coagulation disorders that could underlie hemorrhagic events. [7]
Further research has explored polygenic scores for gestational duration, indicating a complex genetic architecture underlying the timing of parturition. [8] While Mendelian forms of pregnancy complications are less frequently highlighted in the provided context, the concept of inherited variants and gene-gene interactions suggests a multifaceted genetic influence on maternal and fetal health. The study of genetic ancestry is also considered in analyses to account for stratification in genetic studies, underscoring the importance of population-specific genetic backgrounds. [9]
Environmental and Lifestyle Influences
A wide array of environmental and lifestyle factors contribute to the risk of pregnancy complications. Maternal pre-pregnancy body mass index (BMI) is a significant environmental factor, with overweight and obesity being linked to adverse pregnancy outcomes like preterm birth. [9] Nutritional environments, including aspects like protein intake, and non-nutritional exposures, such as endocrine disruptors, have changed over time and can influence developmental timing and overall pregnancy health. [10] Furthermore, specific maternal exposures during pregnancy, such as alcohol consumption or smoking, have been shown to interact with genetic factors, influencing fetal development and potentially increasing the risk of complications .
Socioeconomic factors, often indexed by birth year heterogeneity, can also reflect varying environmental exposures that may mask or modify genetic effects on reproductive health traits like age at menarche. [10] Geographic influences, such as living at high altitudes, have been identified as environmental risk factors for conditions like preeclampsia. [7] Hyperglycemia during pregnancy, as investigated by the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study, is another critical environmental factor that can lead to adverse pregnancy outcomes. [11]
Gene-Environment Interactions
The interplay between an individual's genetic makeup and their environment is a crucial determinant of risk for many pregnancy complications. Gene-environment (GxE) interactions highlight how genetic predispositions can be modulated by external triggers, often explaining a portion of the "missing heritability" in complex traits. [9] For example, specific maternal COL24A1 variants, such as rs11161721, have shown a significant interaction with maternal pre-pregnancy overweight or obesity, substantially increasing the risk of preterm birth. [9] This suggests that the genetic risk conferred by these variants is amplified when combined with an adverse maternal metabolic environment.
Environmental heterogeneity, which varies between and within populations, can obscure genetic effects if not properly accounted for in analyses. [10] Studies have also revealed interactions between genetic risk scores for traits like age at menarche and environmental proxies like birth year, indicating that the impact of genetic factors can change with evolving environmental conditions. [10] Such interactions underscore the importance of considering both genetic and environmental contexts when assessing the risk of pregnancy complications.
Maternal Physiological and Developmental Factors
Maternal physiological status and developmental history significantly contribute to the risk of antepartum hemorrhage and other pregnancy complications. Maternal age is a widely recognized demographic factor that influences pregnancy outcomes. [9] Comorbidities, particularly metabolic conditions, are also critical; hyperglycemia during pregnancy, often leading to gestational diabetes, is strongly linked to adverse pregnancy outcomes. [11] These metabolic changes can affect placental development and function, potentially increasing the risk of hemorrhagic events.
Beyond current health status, early life influences and developmental factors play a foundational role. The long-term effects of the intrauterine environment, reflected in factors like birth weight, can predispose individuals to certain health trajectories that impact future pregnancies. [5] Factors such as age at menarche and menopause, which are indicators of reproductive developmental timing, are also considered in relation to reproductive health outcomes, although the direct link to antepartum hemorrhage is not explicitly detailed in the provided context. [12]
Genetic Predisposition and Molecular Pathways of Intracerebral Hemorrhage
The susceptibility to hemorrhage, particularly intracerebral hemorrhage (ICH), is influenced by a complex interplay of genetic factors and molecular pathways that govern vascular integrity and repair. Key genetic variants, such as those within the APOE gene, are known to impact the risk of both deep and lobar forms of ICH, as well as the extent of bleeding and patient outcome . [13], [14], [15], [16] These APOE polymorphisms also play a role in modulating longitudinal lipid trends that precede ICH, suggesting a metabolic link to vascular fragility. [17] Beyond APOE, common genetic variations in COL4A1/COL4A2, genes crucial for type IV collagen assembly in the vascular basement membrane, are associated with sporadic cerebral small vessel disease, a significant risk factor for ICH . [18] Mutations in COL4A2 can directly impair the secretion of both COL4A1 and COL4A2 proteins, leading to hemorrhagic stroke. [19]
Further genetic insights reveal specific loci influencing ICH risk and severity. A meta-analysis of genome-wide association studies has identified 1q22 as a susceptibility locus for ICH [2], [3] and research indicates that the 17p12 region influences hematoma volume and outcome in spontaneous ICH. [1] Variants in the ACE gene are linked to the risk of ICH recurrence, particularly in cases involving amyloid angiopathy . [20], [21] Additionally, a specific polymorphism in Glutathione peroxidase 1 (C593T) has been associated with lobar ICH, highlighting the role of oxidative stress pathways in disease pathogenesis. [22] Recent exome-wide association studies have also identified nine novel genes as susceptibility loci for early-onset ICH, underscoring the broad genetic landscape underlying this condition. [4]
Cellular and Tissue-Level Pathophysiology of Intracerebral Hemorrhage
The pathophysiology of ICH involves complex processes at cellular and tissue levels, leading to the formation and expansion of hematomas within the brain. [23] A significant component of this pathology involves cerebral small vessel disease, which can manifest as cerebral white matter hyperintensities (WMH) observed in stroke patients . [24], [25] The integrity of brain vascular tissue is maintained by various cell types, including endothelial cells, smooth muscle cells, and pericytes, which are critical for vessel structure and function. [2] Disruptions in these cellular components, particularly within the endothelial basement membrane, can compromise vessel strength. For instance, Lysyl oxidase-like protein-2 plays a role in regulating sprouting angiogenesis and the assembly of type IV collagen in the endothelial basement membrane, thereby influencing vascular stability and potentially hemorrhage risk .
Systemic Factors and Homeostatic Disruptions in Intracerebral Hemorrhage
Systemic physiological factors and disruptions in homeostatic mechanisms significantly contribute to the risk and outcome of intracerebral hemorrhage. Hypertension is a major modifiable risk factor, with a higher burden of risk alleles for hypertension directly increasing the susceptibility to ICH . [26], [27] Beyond genetic predispositions, environmental risk factors also play a role in the incidence of ICH . [28] Furthermore, the location of ICH within the brain is a critical determinant of patient outcome [29] and studies have shown sex-related differences in the occurrence of primary ICH. [30] Therapeutic interventions, such as pre-treatment with statins, have also been investigated for their impact on ICH patient outcomes [31] highlighting the complex interplay between genetic, environmental, and clinical factors in hemorrhage pathology.
Genetic Predisposition and Risk Stratification
Genetic factors play a significant role in determining an individual's susceptibility to intracerebral hemorrhage (ICH), influencing both the risk of developing the condition and its specific characteristics. For instance, variants within the APOE gene are known to influence the risk of both deep and lobar ICH, enabling improved risk assessment for these distinct clinical phenotypes. [14] Furthermore, meta-analyses of genome-wide association studies have identified loci such as 1q22 as a susceptibility locus for ICH, highlighting specific genomic regions that confer increased risk. [3] The cumulative burden of risk alleles associated with hypertension also significantly elevates the risk of ICH, underscoring the interplay between genetic predisposition and established environmental risk factors in identifying high-risk individuals for targeted prevention strategies. [26]
These genetic insights contribute to a more personalized medicine approach by aiding in the identification of individuals at higher risk, potentially before clinical presentation. Understanding these genetic predispositions can inform tailored monitoring strategies and guide lifestyle modifications or pharmacological interventions to mitigate risk. For example, recognizing a patient's APOE genotype can help predict the likelihood of specific ICH subtypes, which may have different underlying etiologies and management implications. [14] Such genetic information, combined with other clinical and environmental risk factors, provides a comprehensive framework for risk stratification and can enhance early intervention efforts.
Prognostic Value and Treatment Guidance
Genetic markers and clinical imaging characteristics offer crucial prognostic information, aiding in predicting disease progression, treatment response, and long-term outcomes for patients with ICH. The APOE genotype, beyond its role in risk, is a strong predictor of the extent of bleeding and overall outcome, particularly in lobar intracerebral hemorrhage, providing valuable insights for patient counseling and acute management. [13] Additionally, specific genetic loci, such as those within the 17p12 region, have been shown to influence hematoma volume and patient outcomes in spontaneous ICH, contributing to a more refined prognostic assessment. [1] Clinically, early indicators like hematoma volume are powerful and easy-to-use predictors of short-term mortality, while the presence of a "spot sign" on computed tomography angiography can predict rapid hematoma expansion, guiding urgent therapeutic interventions. [1]
Integrating these genetic and imaging predictors allows for more informed treatment selection and monitoring strategies. For instance, knowledge of an individual's genetic profile or the characteristics of their hemorrhage could help determine the aggressiveness of blood pressure management or the potential benefit of specific neurosurgical interventions. Studies have also explored the outcome of ICH patients who were pre-treated with statins, suggesting avenues for optimizing pharmacological management based on patient profiles. [31] The ability to predict outcomes and disease progression based on these factors is essential for developing personalized care plans and improving patient prognosis.
Comorbidities and Associated Cerebrovascular Conditions
Intracerebral hemorrhage often co-occurs with or is influenced by other cerebrovascular pathologies, and genetic studies reveal shared underlying mechanisms and overlapping phenotypes. Variants in genes like ACE are associated with the risk of ICH recurrence, particularly in the context of cerebral amyloid angiopathy, highlighting a genetic link between these conditions. [20] Beyond direct ICH risk, genetic variations in regions such as COL4A1/COL4A2 are strongly associated with sporadic cerebral small vessel disease, which is a significant contributor to ICH pathogenesis. [18] Genome-wide association studies have also demonstrated an overlap between genetic loci influencing nonlobar ICH and cerebral white matter hyperintensities, suggesting common genetic susceptibilities for these related cerebrovascular pathologies. [3]
These associations are critical for understanding the broader clinical context of ICH and for comprehensive patient management. Recognizing the genetic links to conditions like amyloid angiopathy or small vessel disease can prompt clinicians to screen for these comorbidities, influencing long-term management and secondary prevention strategies. For example, a patient with ICH and specific genetic variants might require different follow-up protocols or therapeutic approaches to prevent recurrence or manage co-existing cerebrovascular damage. This integrated understanding of genetics and comorbidities facilitates a holistic approach to patient care, addressing not just the acute hemorrhage but also the underlying vascular health.
Frequently Asked Questions About Antepartum Hemorrhage
These questions address the most important and specific aspects of antepartum hemorrhage based on current genetic research.
1. My sister had bleeding during pregnancy; does that mean I will too?
Your sister having bleeding during pregnancy suggests a potential family pattern, but it doesn't guarantee you will experience it. While there can be a genetic component influencing susceptibility to conditions like placenta previa or abruption, many factors contribute. Your individual risk profile is unique, involving a mix of your own genetic makeup, lifestyle, and other health factors. It's always best to discuss family history with your doctor for personalized advice.
2. Why do some pregnant people get serious bleeding, but others don't?
It's a complex interplay of factors! Some individuals have genetic variations that affect things like the strength of their blood vessels, their blood clotting ability, or the integrity of uterine tissues. These genetic predispositions can make some people more susceptible to conditions causing bleeding, while others might have different genetic profiles that offer more protection. Environmental factors and other health conditions also play a significant role.
3. Does my family's ethnic background change my risk for this bleeding?
Yes, your ethnic background can potentially influence your risk. Genetic architectures and allele frequencies for certain traits can vary across different populations. While much of the research has focused on individuals of European descent, it's recognized that different ethnic groups might have unique genetic risk factors that could affect their susceptibility to pregnancy complications. This highlights the need for more diverse genetic studies.
4. Can my daily habits influence my risk for pregnancy bleeding?
Absolutely. Even if you have a genetic predisposition, your daily habits and environment can significantly interact with your genes. Things like overall health, nutrition, and avoiding certain risk factors can influence how those genetic predispositions manifest. It's a prime example of how genetics loads the gun, but lifestyle helps keep it holstered.
5. If I had bleeding in one pregnancy, am I more likely to have it again?
If you've experienced bleeding in a previous pregnancy, you might have an increased risk in subsequent pregnancies due to a combination of genetic and physiological factors. Your genetic makeup could predispose you to issues with placental attachment or vascular integrity, which could recur. Discussing your previous obstetric history with your doctor is crucial for assessing your specific risk and planning care.
6. Is there anything I can do to 'override' my genetic risk for pregnancy bleeding?
While you can't change your inherited genes, you can definitely take steps to manage your overall health and potentially mitigate some risks. Focusing on a healthy lifestyle, managing any pre-existing conditions, and receiving excellent prenatal care are crucial. Understanding your family history can help your doctor monitor you more closely, allowing for early detection and management of potential issues.
7. Could a genetic test before pregnancy predict my bleeding risk?
Currently, routine genetic tests specifically to predict the risk of antepartum hemorrhage before pregnancy are not widely available or recommended. While research is identifying genetic components related to vascular health and tissue strength, the genetic picture is very complex and multifactorial. Such tests would need to be much more comprehensive and validated across diverse populations to be truly predictive.
8. Do my genes affect how severe my pregnancy bleeding might be?
It's plausible that your genes could influence the severity of pregnancy bleeding. Genetic variations impacting vascular integrity, your body's clotting response, or tissue repair mechanisms might contribute to how extensively bleeding occurs or how quickly it can be controlled. However, severity is also heavily influenced by the specific cause of the bleeding and other clinical factors.
9. Why do some bodies seem more prone to placental issues causing bleeding?
This often comes down to subtle genetic differences affecting the development and function of the placenta and uterus. Some individuals may have inherited predispositions that affect the strength of the uterine wall, the way the placenta implants, or the health of the blood vessels at the placental-uterine interface. These genetic factors, combined with other physiological and environmental influences, can increase susceptibility to complications like placenta previa or abruption.
10. Could stress increase my genetic risk for pregnancy bleeding?
While the direct link between stress and genetic risk for antepartum hemorrhage is still being explored, chronic stress can impact various bodily systems, including cardiovascular health and inflammation. It's conceivable that in individuals with a genetic predisposition to issues with vascular health or tissue integrity, high stress levels could potentially exacerbate these underlying vulnerabilities. Managing stress is important for overall pregnancy well-being.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Marini, S. et al. "17p12 Influences Hematoma Volume and Outcome in Spontaneous Intracerebral Hemorrhage." Stroke, vol. 49, 2018, pp. 1599–1606.
[2] Chung, J. et al. "Genome-wide association study of cerebral small vessel disease reveals established and novel loci." Brain, vol. 142, 2019, pp. 3158–3174.
[3] Woo, D. et al. "Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage." Am J Hum Genet, vol. 94, 2014, pp. 511–521.
[4] Yamada, Y., et al. "Identification of nine genes as novel susceptibility loci for early-onset ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage." Biomed Rep, vol. 9, no. 1, 2018, pp. 8-20.
[5] Hayes, M. G., et al. "Identification of HKDC1 and BACE2 as genes influencing glycemic traits during pregnancy through genome-wide association studies." Diabetes, vol. 62, no. 10, 2013, pp. 3605-3613.
[6] Changalidis, A. I., et al. "Aggregation of Genome-Wide Association Data from FinnGen and UK Biobank Replicates Multiple Risk Loci for Pregnancy Complications." Genes (Basel), vol. 13, no. 12, 2022, p. 2255.
[7] Nieves-Colon, M. A., et al. "Clotting factor genes are associated with preeclampsia in high-altitude pregnant women in the Peruvian Andes." Am J Hum Genet, vol. 109, no. 6, 2022, pp. 1017-1033.
[8] Sole-Navais, P., et al. "Genetic effects on the timing of parturition and links to fetal birth weight." Nat Genet, vol. 55, no. 4, 2023, pp. 605-616.
[9] Hong, X., et al. "Genome-wide approach identifies a novel gene-maternal pre-pregnancy BMI interaction on preterm birth." Nat Commun, vol. 8, 2017, p. 15606.
[10] Demerath, E. W., et al. "Genome-wide association study of age at menarche in African-American women." Hum Mol Genet, vol. 22, no. 16, 2013, pp. 3329-3339.
[11] Metzger, B. E., et al. "Hyperglycemia and adverse pregnancy outcomes." N Engl J Med, vol. 358, no. 19, 2008, pp. 1991-2002.
[12] D'Urso, S., et al. "Mendelian randomization analysis of factors related to ovulation and reproductive function and endometrial cancer risk." BMC Med, vol. 20, no. 1, 2022, p. 384.
[13] Biffi, A. et al. "APOE Genotype Predicts Extent of Bleeding and Outcome in Lobar Intracerebral Hemorrhage." Lancet Neurol., vol. 10, 2011, pp. 702–709.
[14] Biffi, A. et al. "Variants at APOE influence risk of deep and lobar intracerebral hemorrhage." Ann. Neurol., vol. 68, 2010, pp. 934–943.
[15] O'Donnell, H.C., Rosand, J., Knudsen, K.A., Furie, K.L., Segal, A.Z., Chiu, R.I., Ikeda, D., and Greenberg, S.M. "Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage." N Engl J Med, vol. 342, 2000, pp. 240–245.
[16] Woo, D., Kaushal, R., Chakraborty, R., Woo, J., Haverbusch, M., Sekar, P., Kissela, B., Pancioli, A., Jauch, E., Kleindorfer, D., et al. "Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage." Stroke, vol. 36, 2005, pp. 1874–1879.
[17] Marini, S., et al. "APOE polymorphisms influence longitudinal lipid trends preceding intracerebral hemorrhage." Neurol Genet, vol. 2, 2016, p. e81.
[18] Rannikmäe, K. et al. "Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease." Neurology, vol. 84, 2015, pp. 918–926.
[19] Jeanne, M., Labelle‑Dumais, C., Jorgensen, J., Kauffman, W.B., Mancini, G.M., Favor, J., Valant, V., Greenberg, S.M., Rosand, J., and Gould, D.B. "COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke." Am J Hum Genet, vol. 90, 2012, pp. 91–101.
[20] Domingues-Montanari, S. et al. "ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy." Neurobiol. Aging, vol. 32, 2011, pp. e13–e22.
[21] Mendioroz, M., Boada, M., Munuera, J., Rovira, A., Maisterra, O., Pare´s, M., Gutierrez, M., et al.; Stroke Project Cerebrovascular Diseases Study Group, Spanish Society of Neurology. "ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy." Neurobiol Aging, vol. 32, 2011, pp. e13–e22.
[22] Pera, J., Slowik, A., Dziedzic, T., Pulyk, R., Wloch, D., and Szczudlik, A. "Glutathione peroxidase 1 C593T polymorphism is associated with lobar intracerebral hemorrhage." Cerebrovasc. Dis., vol. 25, 2008, pp. 445–449.
[23] Schlunk, F., and Greenberg, S.M. "The Pathophysiology of Intracerebral Hemorrhage Formation and Expansion." Transl Stroke Res., vol. 6, 2015, pp. 257–263.
[24] Traylor, M. et al. "Genome-wide meta-analysis of cerebral white matter hyperintensities in patients with stroke." Neurology, vol. 86, 2016, pp. 146–153.
[25] Verhaaren, B.F.J. et al. "Multiethnic Genome-Wide Association Study of Cerebral White Matter Hyperintensities on MRI." Circ Cardiovasc Genet., vol. 8, 2015, pp. 398–409.
[26] Falcone, G.J. et al. "Burden of risk alleles for hypertension increases risk of intracerebral hemorrhage." Stroke, vol. 43, 2012, pp. 2877–2881.
[27] Yamada, Y., Matsui, K., Takeuchi, I., Oguri, M., and Fujimaki, T. "Association of genetic variants with hypertension in a longitudinal population‑based genetic epidemiological study." Int J Mol Med, vol. 35, 2015, pp. 1189‑1198.
[28] Woo, D. et al. "Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study." Stroke, vol. 33, 2002, pp. 1190–1195.
[29] Delcourt, C., Sandset, E.C., Zheng, D., Chen, X., Salman, R.A., Robinson, T., et al. "Intracerebral hemorrhage location and outcome among INTERACT2 participants." Neurology, vol. 88, 2017, pp. 1408–1414.
[30] Roquer, J., Rodriguez-Campello, A., Jimenez-Conde, J., Cuadrado-Godia, E., Giralt-Steinhauer, E., Vivanco Hidalgo, R.M., et al. "Sex-related differences in primary intracerebral hemorrhage." Neurology, vol. 87, 2016, pp. 257–262.
[31] Gomis, M. et al. "Outcome of intracerebral haemorrhage patients pre-treated with statins." Eur J Neurol., vol. 17, 2010, pp. 443–448.